In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.
about
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).
P2860
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
In vivo RAF signal transductio ...... s with neuroendocrine tumours.
@en
type
label
In vivo RAF signal transductio ...... s with neuroendocrine tumours.
@en
prefLabel
In vivo RAF signal transductio ...... s with neuroendocrine tumours.
@en
P2093
P2860
P50
P356
P1476
In vivo RAF signal transductio ...... ts with neuroendocrine tumours
@en
P2093
J Petronis
P2860
P2888
P304
P356
10.1038/BJC.2013.64
P407
P577
2013-02-14T00:00:00Z